Treating OSA in truck drivers lowers healthcare costs and disability rates: Study

NewsGuard 100/100 Score

For commercial motor vehicle drivers with obstructive sleep apnea (OSA), effective treatment lowers healthcare costs and disability rates, reports a study in the May Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

Treating OSA in truck drivers has economic as well as health and safety benefits, according to the new study, led by Dr. Benjamin Hoffman, Chief Medical Officer of Waste Management, Inc.

The researchers used insurance claims records to evaluate the effects of OSA treatment in commercial motor vehicle drivers. Costs were compared for 156 drivers who received continuous positive airway pressure (CPAP) or other treatments for OSA and 92 drivers who were diagnosed with OSA but were not treated.

For treated drivers, health plan costs decreased by an average of $2,700 in the first year and another $3,100 in the second year, compared to no change for untreated drivers. The treated drivers also missed fewer work days (average 4.4 days in the first year) and had lower short-term disability costs ($528 over two years).

On average, treatment for OSA led to "over $6,000 in total health plan and disability cost savings per treated driver," the researchers write. Total costs decreased by 41 percent in drivers treated for OSA (compared to an eight percent decrease in untreated drivers).

Sleep apnea is an important preventable cause of motor vehicle accidents, and studies have found that treatment for OSA can lower the accident rate. Screening and treatment for OSA has recently been recommended for commercial motor vehicle drivers.

The new study suggests that, in addition to lowering accident rates, treating OSA in commercial motor vehicle drivers can reduce health costs, work absences, and short-term disability. Dr. Hoffman and colleagues conclude, "Addressing OSA in the workplace offers the possibility of early identification and intervention for a chronic disease that is associated with increased health benefit utilization."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients